CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM072903
035-os BibID:(cikkazonosító)e0194166 (WOS)000428603100051 (Scopus)85044720189
Első szerző:Kovács György (belgyógyász, gasztroenterológus)
Cím:Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients / Gyorgy Kovacs, Nora Sipeki, Boglarka Suga, Tamas Tornai, Kai Fechner, Gary L. Norman, Zakera Shums, Peter Antal-Szalmas, Maria Papp
Dátum:2018
ISSN:1932-6203
Megjegyzések:Background & aimsTo determine the prognostic potential of classic and novel serologic antibodies regarding unfavorable disease course in a prospective ulcerative colitis (UC) patient cohort, since few and conflicting data are available in the literature regarding this matter.Methods187 consecutive patients were studied prospectively (median follow-up: 135 months) from a single referral IBD center in Hungary. Sera were tested for different IgA/IgG type autoantibodies (anti-neutrophil cytoplasmic [ANCA], anti-DNA-bound-lactoferrin [anti-LFS], anti-goblet cell [anti-GAB] and anti-pancreatic [PAB: anti-CUZD1 and anti-GP2)]) by indirect immunofluorescence technique and for anti-microbial (anti-Saccharomyces cerevisiae [ASCA] IgG/IgA and anti-OMP Plus? IgA) antibodies by enzyme-linked immunosorbent assays.ResultsA total of 73.6%, 62.4% and 11.2% of UC patients were positive for IgA/IgG type of atypical perinuclear-ANCA, anti-LFS and anti-GAB, respectively. Occurrences of PABs were 9.6%, while ASCA IgA/IgG and anti-OMP IgA were 17.6% and 19.8%, respectively. Antibody status was stable over time. IgA type PABs were more prevalent in patients with primary sclerosing cholangitis (37.5% vs. 4.7% for anti-CUZD1 and 12.5% vs. 0% for anti-GP2, p<0.001 for both). IgA type ASCA and anti-CUZD1 antibodies were associated with higher risk of requirement for long-term immunosuppressant therapy in Kaplan-Meier analysis (pLogRank <0.01 for both). However, in multivariate Cox-regression analysis only ASCA IgA (HR: 2.74, 95%CI: 1.46?5.14, p<0.01) remained independent predictor. UC-related hospitalization due to disease activity was only associated with multiple antibody positivity (for 3 or more; HR 2.03 [95% CI: 1.16?3.56]; p = 0.013). None of the individual antibodies or their combination was associated with the risk of development of extensive disease or colectomy.ConclusionEven with low prevalence rates, present study gives further evidence to the role of certain antibodies as markers for distinct phenotype and disease outcome in UC. Considering the result of the multivariate analysis the novel antibodies investigated do not seem to be associated with poor clinical outcome in UC, only a classic antibody, IgA subtype ASCA remained an independent predictor of long-term immunosuppressive therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Plos One. - 13 : 3 (2018), p. 1-18. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Suga Boglárka Tornai Tamás István (1984-) (belgyógyász) Fechner, Kai Norman, Gary L. Shums, Zakera Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:OTKA-115818
OTKA
RH/885/2013
Egyéb
BO/00426/11
Egyéb
IOIBD Research Grant (2012-2015)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM059587
Első szerző:Lakatos Péter (Semmelweis Egyetem)
Cím:Risk matrix for prediction of disease progression in a referral cohort of patients with Crohn's disease / Peter L. Lakatos, Nora Sipeki, Gyorgy Kovacs, Eszter Palyu, Gary L. Norman, Zakera Shums, Petra A. Golovics, Barbara D. Lovasz, Peter Antal-Szalmas, Maria Papp
Dátum:2015
Megjegyzések:BACKGROUND: Early identification of patients with Crohn's disease (CD) at riskfor subsequent complications is essential for adapting treatment strategy. Weaimed to develop a prediction model including clinical and serologic markers for assessing the probability of developing advanced disease in a prospectivereferral CD cohort.PATIENT AND METHODS: 271 consecutive CD patients (42.4% males, median follow-up: 108 months) were included and followed-up prospectively. Anti-Saccharomycescerevisiae antibodies (ASCA IgA/IgG) antibodies were determined by enzyme-linked immunosorbent assay (ELISA). The final analysis was limited to patients withinflammatory disease behaviour at diagnosis. The final definition for advanceddisease outcome was having intestinal resection or disease behaviour progression.RESULTS: ASCA (IgA and/or IgG) status, disease location, and need for earlyazathioprine (AZA) were included in a 3-, 5- and 7-year prediction matrix. Theprobabilities of advanced disease after 5-years varied from 6.2% to 55% dependingon the combination of predictors. Similar findings were obtained in Kaplan-Meier analysis, the combination of ASCA, location and early use for AZA was associated with the probability to develop advanced disease (pLogRank<0.001).CONCLUSION: Our prediction models identified substantial differences in theprobability of developing advanced disease in the early disease course of CD.Markers identified in this referral cohort were different from those previouslypublished in a population-based cohort suggesting that different predictionmodels should be used in referral setting.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ASCA; Crohn's disease; azathioprine; disease progression; referral cohort; serologic antibodies
Megjelenés:Journal of Crohn's & colitis. - 9 : 10 (2015), p. 891-898. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Kovács György (1982-) (belgyógyász, gasztroenterológus) Pályu Eszter (1983-) Norman, Gary L. Shums, Zakera Golovics Petra Anna Lovász Barbara Dorottya Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM058617
Első szerző:Papp Mária (belgyógyász, gasztroenterológus)
Cím:Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn's patients : the importance of specific target antigens (GP2 and CUZD1) / Maria Papp, Nora Sipeki, Tamas Tornai, Istvan Altorjay, Gary L. Norman, Zakera Shums, Dirk Roggenbuck, Kai Fechner, Winfried Stöcker, Peter Antal-Szalmas, Gabor Veres, Peter Laszlo Lakatos
Dátum:2015
ISSN:1873-9946
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
serologic antibodies
anti-pancreatic antibodies
glycoprotein CUZD1
glycoprotein 2
immunoglobulin A
Crohn's disease
ulcerative colitis
disease progression
Megjelenés:Journal of Crohns & Colitis. - 9 : 8 (2015), p. 659-668. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Tornai Tamás István (1984-) (belgyógyász) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Norman, Gary L. Shums, Zakera Roggenbuck, Dirk Fechner, Kai Stocker, Winfried Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Veres Gábor (orvos) Lakatos Péter (Semmelweis Egyetem)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM090167
035-os BibID:(WoS)000518803401187
Első szerző:Sipeki Nóra (általános orvos)
Cím:Gut barrier failure biomarkers in IBD : is there anything new beyond "The Wall"? / N. Sipeki, P. Kovats, B. Balogh, Z. Shums, G. L. Norman, P. Antal-Szalmas, M. Papp
Dátum:2020
ISSN:1873-9946
Megjegyzések:Background: Several defects in the many specialised components of mucosal barrier have been reported in inflammatory bowel disease (IBD). These alterations may represent a primary dysfunction in Crohn's disease(CD), but they may also perpetuate chronic mucosal inflammation in ulcerative colitis(UC). Changes in intestinal permeability can predict IBD course. Methods: We aim to determine the predictive potential of a panel of serological markers that reflect either mechanical or immunological gut barrier dysfunction regarding determination of disease phenotype, therapeutic strategy and long-term disease course in a prospective referral adult IBD patient cohort. Sera of 266 CD (m/f:112/154, median age:25 years, B1:80.1%, P1:18.0%) and 187 UC (m/f:86/101, median age:33 years, extensive colitis:28.3%) patients were assayed for intestinal fatty acidbinding protein(I-FABP) and various immunoglobulin A (IgA) molecules, anti-F-actin[AAA IgA/IgG] and anti-gliadin[AGA IgA/ IgG]) by enzyme-linked immunosorbent assay (ELISA) along with 155 healthy controls (HCONT). Clinical data were available on unfavourable disease outcome as well as disease activity and medical treatment during the prospective follow-up (median: 143 and 135 mths for CD and UC respectively). Results: In UC, median I-FABP level was significantly lower than in HCONT(177.2 vs. 244.3 pg/ml; p < 0.05). sIgA level was higher in both CD and UC compared with HCONT(51.2 and 46.0 vs. 29.2 ?g/ml; p < 0.0001). AAA positivity with IgA type predominance was significantly higher in CD(40.2vs UC:15.7; HCONT:6.2%). AGA was also more prevalent in CD(16.5vs UC:6.7; HCONT:7.2%). There was an association between the presence of IgA type AAA or AGA and antimicrobial antibodies. ACA IgA was also more prevalent in case of AAA IgA positivity(52.9 vs. 32.7%, p = 0.009). PS/PT IgA positivity was higher in AGA IgA positive patients (33.3 vs. 7.6%, p = 0.001). Complicated disease behaviour at sample procurement was associated with the presence of AAA and AGA IgA positivity. In Kaplan?Meier analysis concomitant presence of IgA and IgG type AAA was associated with a shorter time to resective surgery (HR[95% CI]: 2.03[1.06?3.90]) along with a higher risk of a second surgery needed (HR[95% CI]: 2.82[1.14?6.98]). Sensitivity analysis showed that the later remained significant in B1 patients (p = 0.002) and also remained independent predictor in multivariate Cox-regression analysis comprising relevant clinical factors(HR[95% CI]: 2.88[1.07?7.78], p = 0.037). Conclusion: The presence of AAA and AGA reflects the ongoing mucosal damage in IBD rather than has a value in predicting the disease course.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Journal of Crohns & Colitis. - 14 : Suppl1 (2020), p. S296. -
További szerzők:Kováts Patrícia (1995-) Balogh Boglárka (1993-) (belgyógyász) Shums, Zakera Norman, Gary L. Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

5.

001-es BibID:BIBFORM058618
Első szerző:Sipeki Nóra (általános orvos)
Cím:Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease / Nora Sipeki, Laszlo Davida, Eszter Palyu, Istvan Altorjay, Jolan Harsfalvi, Peter Antal Szalmas, Zoltan Szabo, Gabor Veres, Zakera Shums, Gary L. Norman, Peter L. Lakatos, Maria Papp
Dátum:2015
ISSN:1007-9327
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Crohn's disease
Ulcerative colitis
Disease progression
Antiphospholipid antibodies
Anti-[béta]2- Glycoprotein-I antibodies
Anti-phosphatidylserine/ prothrombin
Anti-cardiolipin antibodies
Thrombosis
Megjelenés:World Journal of Gastroenterology. - 21 : 22 (2015), p. 6952-6964. -
További szerzők:Dávida László (belgyógyász) Pályu Eszter (1983-) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Hársfalvi Jolán (1949-) (klinikai biokémikus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Veres Gábor (orvos) Shums, Zakera Norman, Gary L. Lakatos Péter (Semmelweis Egyetem) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

6.

001-es BibID:BIBFORM069781
Első szerző:Tornai Tamás István (belgyógyász)
Cím:Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis / Tamas Tornai, Eszter Palyu, Zsuzsanna Vitalis, Istvan Tornai, David Tornai, Peter Antal-Szalmas, Gary L. Norman, Zakera Shums, Gabor Veres, Antal Dezsofi, Gabriella Par, Alajos Par, Peter Orosz, Ferenc Szalay, Peter L. Lakatos, Maria Papp
Dátum:2017
ISSN:1007-9327
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:World Journal of Gastroenterology. - 23 : 29 (2017), p. 5412-5421. -
További szerzők:Pályu Eszter (1983-) Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Tornai István (1954-) (belgyógyász, gasztroenterológus) Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Norman, Gary L. Shums, Zakera Veres Gábor (orvos) Dezsőfi Antal Pár Gabriella Pár Alajos Orosz Péter (Miskolc) Szalay Ferenc (belgyógyász) Lakatos Péter (Semmelweis Egyetem) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:OTKA-115818
OTKA
MTA-Bolyai János Kutatási Ösztöndíj
Egyéb
ÚNKP-16-3
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1